[go: up one dir, main page]

MX2019002248A - Proteina de union al factor h modificada. - Google Patents

Proteina de union al factor h modificada.

Info

Publication number
MX2019002248A
MX2019002248A MX2019002248A MX2019002248A MX2019002248A MX 2019002248 A MX2019002248 A MX 2019002248A MX 2019002248 A MX2019002248 A MX 2019002248A MX 2019002248 A MX2019002248 A MX 2019002248A MX 2019002248 A MX2019002248 A MX 2019002248A
Authority
MX
Mexico
Prior art keywords
modified
binding protein
factor binding
fhbp
modified factor
Prior art date
Application number
MX2019002248A
Other languages
English (en)
Other versions
MX420767B (es
Inventor
M Tang Christoph
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2019002248A publication Critical patent/MX2019002248A/es
Publication of MX420767B publication Critical patent/MX420767B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a una proteína modificada de unión al factor H (la fHbp), que comprende la fHbp, o una variante de la misma, modificada con la adición de al menos un bucle peptídico exógeno; y ácido nucleico asociado, composiciones y usos. La invención se refiere, además, al tratamiento o prevención de una infección o colonización patógena de un sujeto mediante el uso de la proteína modificada de unión al factor H (la fHbp).
MX2019002248A 2016-08-31 2017-08-31 Proteina de union al factor h modificada MX420767B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1614687.0A GB201614687D0 (en) 2016-08-31 2016-08-31 fHbp scaffold
PCT/GB2017/052535 WO2018042178A1 (en) 2016-08-31 2017-08-31 Modified factor h binding protein

Publications (2)

Publication Number Publication Date
MX2019002248A true MX2019002248A (es) 2019-09-18
MX420767B MX420767B (es) 2025-02-10

Family

ID=57119942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002248A MX420767B (es) 2016-08-31 2017-08-31 Proteina de union al factor h modificada

Country Status (13)

Country Link
US (1) US12497432B2 (es)
EP (1) EP3506934A1 (es)
JP (1) JP7525093B2 (es)
KR (1) KR102643280B1 (es)
CN (1) CN109890412B (es)
AU (1) AU2017319218B2 (es)
BR (1) BR112019003957A2 (es)
CA (1) CA3035159A1 (es)
GB (2) GB201614687D0 (es)
IL (1) IL265078B2 (es)
MX (1) MX420767B (es)
WO (1) WO2018042178A1 (es)
ZA (1) ZA201901862B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110903400A (zh) * 2019-11-08 2020-03-24 苏州微超生物科技有限公司 B群脑膜炎球菌fHBP多变体融合蛋白及其制备方法与应用
CN111533792B (zh) * 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
WO2022071291A1 (ja) * 2020-09-29 2022-04-07 出光興産株式会社 ペプチドタグおよびそれを含むタグ付加タンパク質
IN202321021121A (es) * 2023-03-24 2024-04-19

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
DK1549338T3 (da) * 2002-10-11 2011-03-28 Novartis Vaccines & Diagnostic Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
WO2004053091A2 (en) * 2002-12-10 2004-06-24 Lorantis Ltd. STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES
WO2004067030A2 (en) * 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
BRPI0415025A (pt) * 2003-10-02 2006-12-12 Chiron Srl vacinas lìquidas para sorogrupos meningocócicos múltiplos
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
ATE493437T1 (de) * 2004-07-23 2011-01-15 Novartis Vaccines & Diagnostic Polypeptide für die oligomerisierung von antigenen
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
US9034345B2 (en) * 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
EP2886551A3 (en) * 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
EP2631245A1 (en) * 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
KR20110053314A (ko) * 2008-05-30 2011-05-20 더 유에스에이, 애즈 리프리젠티드 바이 더 세크리터리 오브 더 아미, 온 비하프 오브 월터 리드 아미 수막구균성 다가 천연 외막 소포체 백신, 이의 제조 방법 및 사용 방법
EP2294085A1 (en) * 2008-06-09 2011-03-16 Novartis AG Antibodies against neisserial factor h binding protein
AU2009288095A1 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
BRPI1009828A2 (pt) * 2009-03-24 2019-03-12 Novartis Ag adjuvante de proteína de ligação de fator h meningocócica
WO2010127172A2 (en) * 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
EP3017828A1 (en) * 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
CN102917730A (zh) * 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
EP2544714A1 (en) * 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
CN105315351A (zh) * 2010-03-30 2016-02-10 奥克兰儿童医院及研究中心 改性的h因子结合蛋白（fhbp）及其使用方法
WO2011125015A2 (en) * 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
WO2011161653A1 (en) * 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
PE20140173A1 (es) * 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
EP2797624A1 (en) * 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
ES2750366T3 (es) * 2012-03-08 2020-03-25 Glaxosmithkline Biologicals Sa Ensayo de potencia in vitro para vacunas meningocócicas basadas en proteína
SA115360586B1 (ar) * 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) * 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP2015521595A (ja) * 2012-06-14 2015-07-30 ノバルティス アーゲー 血清群ｘ髄膜炎菌のためのワクチン
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
JP6446377B2 (ja) * 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
WO2014140562A1 (en) * 2013-03-14 2014-09-18 Isis Innovation Limited Immunogenic composition to neisseria
MX369534B (es) * 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
SMT202000704T1 (it) * 2014-02-28 2021-01-05 Glaxosmithkline Biologicals Sa POLIPEPTIDI DI fHbp DI MENINGOCOCCO MODIFICATI
KR102761870B1 (ko) * 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
AU2015352404A1 (en) * 2014-11-28 2017-05-18 Janssen Vaccines & Prevention B.V. Meningitis B vaccine
US10888611B2 (en) * 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
US10183070B2 (en) * 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Also Published As

Publication number Publication date
AU2017319218B2 (en) 2021-10-28
KR102643280B1 (ko) 2024-03-05
CN109890412A (zh) 2019-06-14
AU2017319218A2 (en) 2019-05-02
JP2019526261A (ja) 2019-09-19
US12497432B2 (en) 2025-12-16
US20220112249A1 (en) 2022-04-14
KR20190064577A (ko) 2019-06-10
JP7525093B2 (ja) 2024-07-30
AU2017319218A1 (en) 2019-04-18
GB201903866D0 (en) 2019-05-08
IL265078B2 (en) 2023-08-01
IL265078A (es) 2019-04-30
IL265078B1 (en) 2023-04-01
ZA201901862B (en) 2020-09-30
NZ751995A (en) 2024-03-22
CA3035159A1 (en) 2018-03-08
MX420767B (es) 2025-02-10
BR112019003957A2 (pt) 2019-06-25
EP3506934A1 (en) 2019-07-10
GB2568440A (en) 2019-05-15
GB201614687D0 (en) 2016-10-12
CN109890412B (zh) 2025-04-04
WO2018042178A1 (en) 2018-03-08
GB2568440B (en) 2022-08-17

Similar Documents

Publication Publication Date Title
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
EA202190983A1 (ru) Новое антитело к с-kit
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2019002248A (es) Proteina de union al factor h modificada.
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
MX2015015506A (es) Peptidos antimicrobianos.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
MX2017003117A (es) Particula tipo virus de flavivirus.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX2020009296A (es) Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
MX2020008125A (es) Composiciones que comprenden berberina.
PH12020551618A1 (en) Erenumab compositions and uses thereof
AR106981A1 (es) Una composición antimicrobiana
MX2021013833A (es) Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
CL2021001138A1 (es) L-triyodotironina (t3) para uso en la limitación de la obstrucción microvascular
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende
EA201890209A1 (ru) Композиция, содержащая танины
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
MX2021001361A (es) Composicion liquida de fibrinogeno humano.
EA202092045A1 (ru) Лечение и предупреждение преэклампсии